


Process for the prescribing and dispensing of Fidaxomicin in the management of *Clostridium difficile*

Updated guidance on the management and treatment of *Clostridium difficile* infection issued by Public Health England states that fidaxomicin is the recommended option for patients with recurrent CDI, whether mild, moderate or severe, because of their increased risk of further recurrences.

This process has been discussed and agreed at the:

- DBH FT Drugs & Therapeutics Committee
- DCCG Medicines Management Group
- Doncaster & Bassetlaw Area Prescribing Committee



Approved D&B APC March 2019 V6.0 Review March 2020

Ref: Updated guidance on the management and treatment of *Clostridium difficile* infection issued by Public Health England May 2013